Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Mesothelioma

Aliases
Early-stage Mesothelioma, Pleural Mesothelioma, Subclinical Mesothelioma

113 clinical trials

137 products

18 drugs

1 abstract

Clinical trial
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
Status: Recruiting, Estimated PCD: 2030-04-01
Product
CTX131
Clinical trial
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2025-12-31
Product
CPI-0209
Product
NGM831
Clinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NGM831 and NGM438 plus pembrolizumab
Product
UCMYM802
Product
VT3989
Clinical trial
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-06
Product
IAG933
Clinical trial
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
Status: Completed, Estimated PCD: 2022-06-30
Product
MesoPher
Clinical trial
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Status:
Product
Tazemetostat
Clinical trial
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
NGM831 plus Pembrolizumab
Product
PRT3645
Product
cyclophosphamide
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-11-02
Product
Ipilimumab
Clinical trial
A Phase Ib Clinical Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Cisplatin and Pemetrexed in Treatment-naive Participants With Advanced Malignant Pleural Mesothelioma (KEYNOTE-A17).
Status: Completed, Estimated PCD: 2022-09-21
Product
Nivolumab
Product
OT-101
Product
gavo-cel
Product
fludarabine
Clinical trial
Phase 2 Trial of TGF-β Inhibition (OT-101) With Anti-PD-1 (Pembrolizumab) in Patients With Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Product
Pembrolizumab
Product
Pemetrexed
Product
Cisplatin
Product
INCB099318
Clinical trial
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-01-30
Clinical trial
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
NGM438
Clinical trial
A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Status: Recruiting, Estimated PCD: 2025-04-01
Product
RSO-021
Product
TC-510
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-10-30
Product
Fludarabine
Product
Cyclophosphamide
Clinical trial
A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants
Status: Recruiting, Estimated PCD: 2026-10-07
Product
Carboplatin
Clinical trial
A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-31
Product
SGN-BB228
Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Product
Naptumomab estafenatox
Product
Obinutuzumab
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
SO-C101
Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Recruiting, Estimated PCD: 2028-06-01
Product
A2B694
Clinical trial
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Status: Recruiting, Estimated PCD: 2026-07-01
Product
NM32-2668
Clinical trial
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-31
Product
MT-8421
Clinical trial
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Status: , Estimated PCD: 2025-11-03
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Irinotecan
Product
Lurbinectedin
Product
pembrolizumab
Clinical trial
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Status: Recruiting, Estimated PCD: 2027-05-04
Product
Naptumomab estafenatox and Durvalumab
Product
NGM831 plus pembrolizumab
Product
NGM831 and NGM438 plus Pembrolizumab
Clinical trial
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-11
Product
TAK-500
Product
VS-6063
Clinical trial
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
Status: Recruiting, Estimated PCD: 2026-02-20
Product
KFA115
Clinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Product
CTX-471
Clinical trial
An Open Label Window of Opportunity Phase II Study of the FAK Inhibitor Defactinib VS-6063 in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
Status: Terminated, Estimated PCD: 2019-06-19
Product
HFB200301
Product
Tislelizumab
Product
SynKIR-110
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Status: Recruiting, Estimated PCD: 2026-03-15
Product
NGM831 + Pembrolizumab
Clinical trial
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Product
VMD-928
Product
XmAb20717
Product
Safety
Product
Expansion Cohort
Clinical trial
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Status: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Completed, Estimated PCD: 2011-06-30
Product
MORAb-009
Clinical trial
Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Status: Completed, Estimated PCD: 2022-08-15
Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-06-01
Product
Itraconazole
Product
Rifampin
Clinical trial
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Status: Completed, Estimated PCD: 2020-03-25
Product
Milademetan
Product
Atezolizumab
Clinical trial
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-03
Clinical trial
A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)
Status: Withdrawn, Estimated PCD: 2023-05-30
Product
ADI-PEG 20 plus Pem Platinum
Product
NGM707
Clinical trial
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Product
AdV-tk + Valacyclovir
Clinical trial
A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Status: Completed, Estimated PCD: 2015-12-01
Clinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2020-08-31
Clinical trial
Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid Tumours
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
CA9hu-1
Product
INCB001158
Product
NGM707 plus Pembrolizumab
Product
AG-01
Product
MRTX1719
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
Status: Recruiting, Estimated PCD: 2026-06-01
Product
CK-301
Clinical trial
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status: Recruiting, Estimated PCD: 2021-11-18
Product
APG-5918
Clinical trial
A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Product
AMT-151
Product
APG-2449
Clinical trial
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-01-23
Product
TBio-6517
Clinical trial
Surgery for Mesothelioma After Radiation Therapy Using Exquisite Systemic Therapy
Status: Recruiting, Estimated PCD: 2025-07-30
Drug
cyclophosphamide
Product
Tremelimumab
Drug
AN0025
Clinical trial
A Phase II Prospective, Open-label Trial of Perioperative Combination Nivolumab and Ipilimumab in Patients With Resectable Malignant Peritoneal Mesothelioma
Status: Completed, Estimated PCD: 2023-04-13
Clinical trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
Standard Chemotherapy
Product
Ipilimumab + Nivolumab
Clinical trial
A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2023-04-24
Drug
Cisplatin
Clinical trial
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Status: , Estimated PCD: 2019-06-07
Clinical trial
A Phase 2 Study of Transarterial Chemoperfusion Treatment With Cisplatin, Methotrexate and Gemcitabine in Patients With Unresectable Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2021-10-16
Product
Methotrexate
Drug
Gemcitabine
Clinical trial
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma
Status: Recruiting, Estimated PCD: 2026-02-11
Product
Malignant Pleural Mesothelioma
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Product
BGC515
Clinical trial
Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Brentuximab Vedotin
Clinical trial
A Phase 1 Study of Pembrolizumab Plus Cryoablation in Patients With Unresectable Mesotheliomas
Status: Completed, Estimated PCD: 2023-12-18
Clinical trial
First-line Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Malignant Pleural Mesothelioma：Multi-Institutional, Single-Arm Phase 2 Trial
Status: Not yet recruiting, Estimated PCD: 2026-04-30
Product
Lenvatinib
Product
Cisplatin/Carboplatin
Clinical trial
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Status: Terminated, Estimated PCD: 2021-12-06
Product
LMB-100
Drug
ipilimumab
Clinical trial
GPC3/Mesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-11-30
Product
Cell therapy
Clinical trial
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Product
iCasp9M28z T cell infusions
Product
Diphenhydramine
Product
Famotidine
Product
Acetaminophen
Product
Dexamethasone
Clinical trial
A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HTL0039732
Drug
pembrolizumab
Clinical trial
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
Atezolizumab
Clinical trial
Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
177Lu-DOTA-TATE
Clinical trial
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group
Status: Active (not recruiting), Estimated PCD: 2024-03-26
Product
Nintedanib
Product
Placebo
Clinical trial
Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299
Status: Terminated, Estimated PCD: 2022-05-11
Product
Ramucirumab
Clinical trial
Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Decitabine/cedazuridine
Clinical trial
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)
Status: Active (not recruiting), Estimated PCD: 2025-03-15
Product
UV1 vaccine
Drug
nivolumab
Clinical trial
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-09-30
Product
VET3-TGI
Clinical trial
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Status: Completed, Estimated PCD: 2014-04-27
Product
PF-03446962
Clinical trial
Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Galinpepimut-S
Product
Sargramostim
Clinical trial
Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) With Porfimer Sodium (Photofrin) in Patients With Malignant Mesothelioma or Non-Small Cell Lung Cancer (NSCLC), or Other Malignancies With Pleural Disease - Phase I Study
Status: Active (not recruiting), Estimated PCD: 2023-11-13
Product
Porfimer Sodium
Clinical trial
Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and Tremelimumab With Chemotherapy for Potentially Resectable Pleural Mesothelioma
Status: Not yet recruiting, Estimated PCD: 2028-05-31
Product
Durvalumab + Tremelimumab
Product
Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
PRO1184
Clinical trial
Niraparib Efficacy in Patient With Unresectable Mesothelioma: A Randomised Phase II Trial of Niraparib Versus Active Symptom Control in Patients With Previously Treated Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Niraparib
Clinical trial
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
Phase I Clinical Trial Testing the Dose Escalation and Expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration for the Management of Pleural Carcinosis
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cisplatine Teva
Clinical trial
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
Status: Completed, Estimated PCD: 2022-08-30
Clinical trial
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
Pemetrexed + Cisplatin/Carboplatin
Clinical trial
Observation of the Efficacy and Safety of Oncolytic Adenovirus Injection Combined With Programmed Death Receptor Inhibitors in Treatment of Advanced Malignant Pleural Mesothelioma : a Single Center, Prospective, Case Registration Study
Status: Recruiting, Estimated PCD: 2026-07-31
Product
Oncolytic Adenovirus H101
Product
Programmed death receptor-1 inhibitor
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Spartalizumab
Clinical trial
An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers
Status: Withdrawn, Estimated PCD: 2025-04-30
Product
Regorafenib
Clinical trial
A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma
Status: Terminated, Estimated PCD: 2021-12-31
Drug
mFOLFOX6
Clinical trial
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Status: Completed, Estimated PCD: 2020-02-16
Clinical trial
First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
Dendritic cell vaccination plus Chemotherapy
Clinical trial
Pemetrexed Plus Gemcitabine Or Carboplatin In Patients With Advanced Malignant Mesothelioma: A Randomized Phase II Trial
Status: Completed, Estimated PCD: 2009-09-01
Product
Gemcitabine
Drug
carboplatin
Clinical trial
Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study
Status: Completed, Estimated PCD: 2016-04-25
Product
Autologous Dendritic Cell Vaccination
Product
DC-CIK Immunotherapy
Clinical trial
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
Status: Recruiting, Estimated PCD: 2024-10-15
Product
Olaparib
Clinical trial
Switch-Maintenance Gemcitabine After First-Line Chemotherapy (Pemetrexed-Platinum) In Patients With Malignant Pleural Mesothelioma In Ain Shams University Hospitals
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma
Status: Completed, Estimated PCD: 2009-06-01
Drug
Docetaxel
Clinical trial
MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI
Status: Recruiting, Estimated PCD: 2027-04-03
Product
Magnesium sulfate
Drug
Varlilumab
Clinical trial
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Checkpoint Blockade Immune
Product
Vinorelbine
Clinical trial
A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)
Status: Completed, Estimated PCD: 2015-01-01
Product
Standard Chemotherapy (Pemetrexed and Cisplatin)
Product
Standard Chemotherapy + Bevacizumab
Clinical trial
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Product
Rucaparib
Product
Abemaciclib
Product
Pembrolizumab & Bemcentinib
Product
Atezolizumab & Bevacizumab
Product
Dostarlimab and Niraparib
Clinical trial
Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma
Status: Terminated, Estimated PCD: 2023-06-05
Product
pevonedistat
Product
Pemetrexed + Cisplatin
Clinical trial
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-07-31
Drug
INCB099280
Clinical trial
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations
Status: Not yet recruiting, Estimated PCD: 2030-01-01
Product
SW-682
Product
Combination Therapy
Clinical trial
A Phase II, Open-Label, Single Arm, Prospective, Multicenter Study of Niraparib Plus Dostarlimab in Patients With Advanced NSCLC and/or MPM, and Positive for PD-L1 Expression and Germline or Somatic Mutations in the HRR Genes
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Niraparib + Dostarlimab
Clinical trial
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
Status: Active (not recruiting), Estimated PCD: 2026-03-31
Drug
cetuximab
Product
Temsirolimus
Product
Valproic Acid
Clinical trial
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Status: , Estimated PCD: 2025-04-01
Clinical trial
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma
Status: Terminated, Estimated PCD: 2016-06-01
Product
BIW-8962
Clinical trial
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Recruiting, Estimated PCD: 2025-12-01
Product
INBRX-109
Drug
fluorouracil
Drug
mFOLFOXIRI
Product
TMZ
Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-11-01
Product
SGN-MesoC2
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10247
Clinical trial
A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-09-23
Product
Bemcentinib
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-03-30
Product
PF-06952229
Drug
enzalutamide
Clinical trial
Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Diffuse Pleural Mesothelioma
Status: Recruiting, Estimated PCD: 2029-06-21
Product
Sacituzumab govitecan